Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Loomis Sayles & Co. L P

Loomis Sayles & Co. L P lowered its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 6.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 150,337 shares of the company's stock after selling 9,933 shares during the period. Loomis Sayles & Co. L P owned approximately 0.15% of Neurocrine Biosciences worth $17,322,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Renaissance Technologies LLC boosted its position in shares of Neurocrine Biosciences by 9.6% in the second quarter. Renaissance Technologies LLC now owns 2,468,146 shares of the company's stock worth $339,790,000 after buying an additional 216,500 shares during the period. AQR Capital Management LLC grew its position in Neurocrine Biosciences by 23.0% in the second quarter. AQR Capital Management LLC now owns 1,223,055 shares of the company's stock valued at $166,959,000 after acquiring an additional 228,444 shares in the last quarter. Bank of New York Mellon Corp grew its position in Neurocrine Biosciences by 1.4% in the second quarter. Bank of New York Mellon Corp now owns 934,404 shares of the company's stock valued at $128,639,000 after acquiring an additional 13,069 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Neurocrine Biosciences by 4.7% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 819,968 shares of the company's stock valued at $94,478,000 after purchasing an additional 37,098 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of Neurocrine Biosciences by 40.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 710,600 shares of the company's stock worth $97,828,000 after purchasing an additional 203,934 shares in the last quarter. Institutional investors and hedge funds own 92.59% of the company's stock.

Neurocrine Biosciences Trading Up 0.6 %

Shares of NASDAQ NBIX opened at $127.91 on Wednesday. Neurocrine Biosciences, Inc. has a 12-month low of $110.52 and a 12-month high of $157.98. The company has a market cap of $12.95 billion, a price-to-earnings ratio of 34.29 and a beta of 0.35. The stock's 50 day simple moving average is $118.83 and its 200 day simple moving average is $131.74.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. BMO Capital Markets dropped their price target on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research note on Thursday, October 17th. Jefferies Financial Group boosted their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a "buy" rating in a research note on Monday, August 19th. Guggenheim raised their price objective on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research note on Friday, August 2nd. JPMorgan Chase & Co. upped their target price on Neurocrine Biosciences from $173.00 to $181.00 and gave the company an "overweight" rating in a research report on Wednesday, August 7th. Finally, Robert W. Baird raised their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an "outperform" rating in a research report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.